Clinical Trials in the USA / NCT07060911
Starting soon
Not applicable
Pivotal Study to Assess Safety and Performance of Neola®, a Novel Lung Monitoring Device for Neonates
NCT07060911 · tracked via the Priya Life Science USA tracker
Condition(s) studied
RDS of PrematurityPreterm BirthLung Diseases
Investigational drug(s) / intervention(s)
Lung monitoring with the Neola device
Lung monitoring with the Neola device: Lung monitoring with the Neola device
Study summary
Pivotal study to assess safety and performance of Neola®, a novel lung monitoring device for neonates
Eligibility
IInclusion criteria:
* Preterm or term born neonates with gestational age between 26 and 40 weeks
* Age between 1 day post-natal and 44 weeks corrected gestational age
* Weight between 1000 g and 3500 g
* Patient treated at a neonatal intensive care unit.
* Patient is either on invasive mechanical ventilation, on CPAP or NIPPV or receives respiratory support via high-flow nasal cannula (≥2L/min)
* Signed informed consent prior to any study related procedures by the legal representatives of the patient
Exclusion criteria:
* Known cardiopulmonary congenital anomalies
* Patients with trisomies or other chromosomal abnormality
* Patients not expected to survive
* Non-intact skin or other skin conditions (such as skin lesions) that do not allow the use of skin adhesives. (e.g., Bullous impetigo, Staphylococcal scalded skin syndrome, localized lesions of herpes simplex virus)
* Thorax curvature does not allow placement of the probe sets without air between the surface of the probes and the skin.
Primary outcome measure(s)
- The number of device related events including skin reactions — 2 days
The primary objective of the study is to evaluate safety with regards to adverse events (AE) and in particular device related adverse events. Outcome measure: The number of device related events including skin reactions. - The number of serious and non-serious adverse events occurring during the trial — 2 days
The primary objective of the study is to evaluate safety with regards to adverse events (AE) and in particular device related adverse events. Outcome measure: The number of serious and non-serious adverse events occurring during the trial.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Stanford Lucile Packard Children's Hospital Neonatal Intensive Care Unit | Palo Alto | California | |
| Cooper Health System | Camden | New Jersey |
Other trials for the same condition
Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs
Active, not recruiting
A Study of Mosliciguat in PH-ILD
Active, not recruiting
Data Collection For Adventitious Lung Sounds Algorithm Using Eko Digital Devices in a Clinical Setting
Active, not recruiting
MIRACLE of LIFE Study
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07060911 on ClinicalTrials.gov ↗ ← All trials in the USA